HTG Molecular Diagnostics Inc (NASDAQ:HTGM) shares rose 3.2% during mid-day trading on Tuesday . The company traded as high as $5.65 and last traded at $5.38. Approximately 2,332,948 shares traded hands during mid-day trading, an increase of 7% from the average daily volume of 2,181,086 shares. The stock had previously closed at $5.56.
HTGM has been the subject of a number of recent research reports. HC Wainwright set a $6.00 price target on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Zacks Investment Research downgraded shares of HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Finally, Canaccord Genuity lifted their price target on shares of HTG Molecular Diagnostics to $5.00 in a research note on Friday, January 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $5.31.
The stock has a market capitalization of $129.10, a P/E ratio of -2.11 and a beta of 1.43.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.